Andrew Freistein 10/804,505

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptabf1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:18:31 ON 03 FEB 2006

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:18:39 ON 03 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 FEB 2006 HIGHEST RN 873294-13-4
DICTIONARY FILE UPDATES: 1 FEB 2006 HIGHEST RN 873294-13-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10804505\e.str





chain nodes :

```
7  9  13  15  17  18  20
ring nodes :
1  2  3  4  5  6  8  10  11  12
chain bonds :
1-20  2-13  3-18  5-7  7-8  7-9  13-17
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-10  8-12  10-11  11-12
exact/norm bonds :
1-20  2-13  3-18  7-8  7-9  8-10  8-12  10-11  11-12  13-17
exact bonds :
5-7
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


G1:H,[*1]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:Atom  9:CLASS  10:Atom
11:Atom  12:Atom  13:CLASS  15:CLASS  17:CLASS  18:CLASS  20:CLASS
Generic attributes :
15:
Number of Carbon Atoms : less than 7




L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR
```



Ak 1

```
G1 H,[@1]


Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 14:18:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    19769 TO ITERATE

 10.1% PROCESSED     2000 ITERATIONS                          0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
```

Andrew Freistein 10/804,505

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 386964 TO 403796
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:19:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 393651 TO ITERATE

100.0% PROCESSED 393651 ITERATIONS 37 ANSWERS
SEARCH TIME: 00.00.08

L3 37 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'HCAPLUS' ENTERED AT 14:19:16 ON 03 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 3 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 2 Feb 2006 (20060202/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4 20 L3

=> d ibib abs hitstr 1-20

L4 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1232819 HCAPLUS
DOCUMENT NUMBER: 144:102803
TITLE: Different Transition-State Structures for the Reactions of β-Lactams and Analogous β-Sultams with Serine β-Lactamases
AUTHOR(S): Tsang, Wing Y.; Ahmed, Naveed; Hinchliffe, Paul S.; Wood, J. Matthew; Harding, Lindsay P.; Laws, Andrew P.; Page, Michael I.
CORPORATE SOURCE: Department of Chemical and Biological Sciences, University of Huddersfield, Queensgate /Huddersfield, HD1 3DH, USA
SOURCE: Journal of the American Chemical Society (2005), 127(49), 17556-17564
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB β-Sultams are the sulfonyl analogs of β-lactams, and N-acyl β-sultams are novel inactivators of the class C β-lactamase of Enterobacter cloacae P99. They sulfonylate the active site serine residue to form a sulfonate ester which subsequently undergoes C-O bond fission and formation of a dehydroalanine residue by elimination of the sulfonate anion as shown by electrospray ionization mass spectroscopy. The analogous N-acyl β-lactams are substrates for β-lactamase and undergo enzyme-catalyzed hydrolysis presumably by the normal acylation-deacylation process. The rates of acylation of the enzyme by the β-lactams, measured by the second-order rate constant for hydrolysis, kcat/Km, and those of sulfonylation by the β-sultams, measured by the second-order rate constant for inactivation, ki, both show a similar pH dependence to that exhibited by the β-lactamase-catalyzed hydrolysis of β-lactam antibiotics. Electron-withdrawing groups in the aryl residue of the leaving group of N-aroyl β-lactams increase the rate of alkaline hydrolysis and give a Bronsted βlg of -0.55, indicative of a late transition state for rate-limiting formation of the tetrahedral intermediate. Interestingly, the corresponding Bronsted βlg for the β-lactamase-catalyzed hydrolysis of the same substrates is -0.06, indicative of an earlier transition state for the enzyme-catalyzed reaction. By contrast, although the Bronsted βlg for the alkaline hydrolysis of N-aroyl β-sultams is -0.73, similar to that for the β-lactams, that for the sulfonylation of β-lactamase by these compds. is -1.46, compatible with significant amide anion expulsion/S-N fission in the transition state. In this case, the enzyme reaction displays a later transition state compared with hydroxide-ion-catalyzed hydrolysis of the β-sultam.

IT **873073-29-1P**
RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(different transition-state structures for reactions of β-lactams and analogous β-sultams with serine β-lactamases)
RN 873073-29-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

L4 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:823313 HCAPLUS
DOCUMENT NUMBER: 143:229708
TITLE: A preparation of azetidine derivatives, useful as COX-1/COX-2 inhibitors
INVENTOR(S): Altisen, Rosa Cuberes; Constansa, Jordi Frigola; Alvarez, Mathieu Ines
PATENT ASSIGNEE(S): Spain
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005182041	A1	20050818	US 2004-804505	20040319
ES 2244313	A1	20051201	ES 2004-363	20040216
WO 2005077896	A1	20050825	WO 2005-EP1657	20050216

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: ES 2004-363 A 20040216
US 2004-804505 A 20040319

OTHER SOURCE(S): MARPAT 143:229708
GI



I



II

L4 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
AB The invention relates to a preparation of azetidine derivs. of formula I [wherein: A is C(O), CH2, or CH2C(O) bonded to azetidine via carbonyl carbon atom; R1 and R3 are independently H or aliphatic group; R2 is H, OH, or alkoxy; R4 is H, aryl, or aliphatic group; R5 and R6 are independently selected from H, halogen, OH, aliphatic group, or NH2, etc.], useful as COX-1/COX-2 inhibitors. For instance, azetidine derivative II (rats, analgesia test: ED50 = 0.4 mg/kg, test for activity against edema: ED50 = 3 mg/kg, antiarthritic activity: ED50 = 0.5 mg/kg) was prepared via amidation of 3,5-di-tert-butyl-4-hydroxybenzoyl chloride by azetidin-3-ol hydrochloride with a yield of 30%.

IT **862780-46-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of azetidine derivs. useful as COX-1/COX-2 inhibitors)
RN 862780-46-9 HCAPLUS
CN 3-Azetidinol, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]- (9CI) (CA INDEX NAME)



IT **862780-47-0P 862780-52-7P 862780-55-0P**
862780-56-1P 862780-57-2P 862780-58-3P
862780-60-7P 862780-61-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azetidine derivs. useful as COX-1/COX-2 inhibitors)
RN 862780-47-0 HCAPLUS
CN 3-Azetidinol, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 862780-52-7 HCAPLUS
CN Acetamide, N-[(2S,3R)-1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]-2-methyl-3-azetidinyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 862780-55-0 HCAPLUS
CN 3-Azetidinol, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 862780-56-1 HCAPLUS
CN Azetidine, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]-3-bromo- (9CI) (CA INDEX NAME)



RN 862780-57-2 HCAPLUS
CN 3-Azetidinol, 1-[3,5-bis(1,1-dimethylethyl)-4-methoxybenzoyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 862780-58-3 HCAPLUS
CN 3-Azetidinol, 1-[4-hydroxy-3,5-bis(1-methylethyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 862780-60-7 HCAPLUS
CN 3-Azetidinol, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 862780-61-8 HCAPLUS
CN 3-Azetidinol, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]-3-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:928619 HCAPLUS
DOCUMENT NUMBER: 142:56031
TITLE: Cyclopropyl building blocks for organic synthesis, 102. A convenient new synthesis of 3-substituted β-lactams formally derived from 1-(aminomethyl)cyclopropanecarboxylic acids
AUTHOR(S): Zanobini, Alessandra; Gensini, Martina; Magull, Joerg; Vidovic, Denis; Kozhushkov, Sergei I.; Brandi, Alberto; de Meijere, Armin
CORPORATE SOURCE: Institut fuer Organische und Biomolekulare Chemie, Georg-August-Universitaet, Goettingen, 37077, Germany
SOURCE: European Journal of Organic Chemistry (2004), (20), 4158-4166
CODEN: EJOCFK; ISSN: 1434-193X
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:56031

AB 1,3-Dipolar cycloaddn. of N-benzyl-C-(methoxycarbonyl)-nitrone, N-benzyl-C-phenylnitrone, N-benzyl-C-cyanonitrone, N-(p-methoxybenzyl)-C-cyanonitrone, N-phenyl- and N-(2-pyridyl)-C-methylnitrones to bicyclopropylidene gave the corresponding cycloadducts. Treatment of these bisspirocyclopropanated isoxazolidines with trifluoroacetic acid in acetonitrile furnished the corresponding 3-spirocyclopropanated β-lactams. The structures of one cycloadduct and a β-lactam were proven by x-ray crystal structure analyses. Thus, this new method furnishes compds. with a 5-azaspiro[2.3]hexan-4-one skeleton in 68-94% overall yield in two simple steps, β-Lactams were converted into their N-acyl derivs. Heating of the β-lactams with tert-Bu glycinate or tert-Bu (S)-phenylalaninate in DMF led to ring-opening of the β-lactam moiety to give β-dipeptides or amide. Some β-Lactams turned out not to be transformable into such peptide products.

IT **808770-86-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of cyclopropyl building blocks for the synthesis of 3-substituted β-lactams via 1,3-dipolar cycloaddn. and ring opening reactions)

RN 808770-86-7 HCAPLUS
CN 5-Azaspiro[2.3]hexane-4-carbonitrile, 5-(4-methoxybenzoyl)-6-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:310829 HCAPLUS
DOCUMENT NUMBER: 140:303552
TITLE: Preparation of β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
INVENTOR(S): Duan, Jingwu; King, Bryan W.; Decicco, Carl; Maduskuie, Thomas P.; Voss, Mathew E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 150 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004072802	A1	20040415	US 2002-267207	20021009
PRIORITY APPLN. INFO.:			US 2002-267207	20021009

OTHER SOURCE(S): MARPAT 140:303552

AB Novel β-amino acid derivs. A-CR3R4aCR2R4NR1CO-X-Z-Ua-Xa-Ya-Za [A = CO2H, SH, CH2SH, S(O)Ra:NH (Ra = H, alkyl), P(O)(OH)2, etc.; X, Xa is absent or alkylene, alkenylene or alkynylene; Z is absent or substituted C3-13 carbocycle or 5-14 membered heterocycle; Ua is absent or O, NRal [Ral = H, (un)substituted alkyl, alkenyl or alkynyl; Ra and Ral may form a ring], CO, CO2, O2C, CONRal, S(O)p (p = 0-2), etc.; Ya is absent or O, NRal, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered heterocycle; R1 is H, alkyl, Ph, benzyl; R2 is Q (Q is H, substituted carbocycle or heterocycle), alkylene-Q, (CRaRal)r1O(CRaRal)r-Q (r, r1 = 0-4), (CRaRal)r1NRa(CRaRal)r-Q, etc.; R3 = Q1 (Q1 is any group given for Q), alkylene-Q1, (CRaRal)r1O(CRaRal)r-Q1, (CRaRal)r1NRa(CRaRal)r-Q1, etc.; R4, R4a = H, substituted alkyl, alkenyl or alkynyl; alternatively R1 and R2, R1 and R3, R3 and R4a may form rings (with provisos)] or a stereoisomer or pharmaceutically acceptable salt were prepared as metalloprotease and TNF-α inhibitors. Thus, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-3-azetidinecarboxamide was prepared by a multistep procedure involving reactions of Me 4-hydroxyphenylacetate, 2-methyl-4-quinolinylmethanol, and 3-azetidinecarboxylic acid Me ester.

IT **362697-32-3P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)

RN 362697-32-3 HCAPLUS
CN 3-Azetidinecarboxamide, N-hydroxy-1-[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **362703-18-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)
RN 362703-18-2 HCAPLUS
CN 3-Azetidinecarboxylic acid, 1-[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:60463 HCAPLUS
DOCUMENT NUMBER: 140:111265
TITLE: Preparation of azetidinecarboxylic acid and pyrrolidinecarboxylic acid N-hydroxyamide derivatives as antibacterial agents
INVENTOR(S): Raju, Bore G.; Odowd, Hardwin; Gao, Hongwu; Patel, Dinesh V.; Trias, Joaquim
PATENT ASSIGNEE(S): Vicuron Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007444	A2	20040122	WO 2003-US21838	20030711
WO 2004007444	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492035	AA	20040115	CA 2003-2492035	20030711
EP 1539744	A2	20050615	EP 2003-748939	20030711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005536510	T2	20051202	JP 2004-521744	20030711
PRIORITY APPLN. INFO.:			US 2002-394862P	P 20020711
			WO 2003-US21838	W 20030711

OTHER SOURCE(S): MARPAT 140:111265
GI

L4 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II



III

AB Title compds. I or II [wherein A = (hetero)aryl; X1-X4 = independently H, (halo)alkyl, (halo)alkylthio, (halo)alkylsulfinyl, (halo)alkylsulfonyl, hydroxy(alkyl), alkoxy(alkyl), haloalkoxy, alkenyl, alkenyloxy(alkyl), alkynyl(oxy), NO2, halo, cycloalkyl(alkyl), arylalkoxy(alkyl), haloarylalk(yn)yl, alkylsilylalkynyl, aryl, aminocarbonylalkyl, carboxylate, carboxy, carboxamido, or (un)substituted heterocyclyl; R1 and R3 = independently H, (halo)alkyl, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, halo, OH, alkoxy, or (un)substituted (hetero)aryl or aryloxy; R2 = H, (halo)alkyl, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, halo, OH, alkoxy, or (un)substituted (hetero)aryl or aryloxy; ; Z = CH2 or CO; and pharmaceutically acceptable salts, tautomers, and prodrugs thereof] were prepared as inhibitors of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC deacetylase), an enzyme present in gram neg. bacteria (no data). For example, azetidine-2R-carboxylic acid Me ester hydrochloride salt was coupled with 3,4-dimethoxy-5-propylbenzoic acid in DMF to give the benzoylazetidinyl derivative (81%). The ester was treated with aqueous hydroxylamine in dioxane to afford III. Preferred compds. of the invention have MIC ≤ 128 μg/mL against at least one of a specified list of bacteria (no data). Thus, I, II, and their pharmaceutical compns. are useful as antimicrobials and antibiotics (no data).

IT **647856-14-2P**, (R)-1-(3,5-Diallyl-4-methoxybenzoyl)azetidine-2-carboxylic acid hydroxyamide **647856-15-3P**, (R)-1-(4-Methoxy-3,5-dipropylbenzoyl)azetidine-2-carboxylic acid hydroxyamide **647856-18-6P**, (R)-1-(4-Methoxy-3-propylbenzoyl)azetidine-2-carboxylic acid hydroxyamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial agent; preparation of azetidinecarboxylic acid and pyrrolidinecarboxylic acid N-hydroxyamide derivs. as antibacterial agents)

L4 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 647856-14-2 HCAPLUS
CN 2-Azetidinecarboxamide,
N-hydroxy-1-(4-methoxy-3,5-di-2-propenylbenzoyl)-,
(2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 647856-15-3 HCAPLUS
CN 2-Azetidinecarboxamide, N-hydroxy-1-(4-methoxy-3,5-dipropylbenzoyl)-,
(2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 647856-18-6 HCAPLUS
CN 2-Azetidinecarboxamide, N-hydroxy-1-(4-methoxy-3-propylbenzoyl)-, (2R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **647856-16-4**, (R)-1-(3,5-Diallyl-4-methoxybenzoyl)azetidine-2-
carboxylic acid methyl ester

L4 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azetidinecarboxylic acid and pyrrolidinecarboxylic acid
N-hydroxyamide derivs. as antibacterial agents)
RN 647856-16-4 HCAPLUS
CN 2-Azetidinecarboxylic acid, 1-(4-methoxy-3,5-di-2-propenylbenzoyl)-,
methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:887103 HCAPLUS
DOCUMENT NUMBER: 140:93653
TITLE: An Evaluation of Amide Group Planarity in 7-Azabicyclo[2.2.1]heptane Amides. Low Amide Bond Rotation Barrier in Solution
AUTHOR(S): Otani, Yuko; Nagae, Osamu; Naruse, Yuji; Inagaki, Satoshi; Ohno, Masashi; Yamaguchi, Kentaro; Yamamoto, Gaku; Uchiyama, Masanobu; Ohwada, Tomohiko
CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo, Tokyo, 113-0033, Japan
SOURCE: Journal of the American Chemical Society (2003), 125(49), 15191-15199
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:93653
AB Here we show that amides of bicyclic 7-azabicyclo[2.2.1]heptane are intrinsically nitrogen-pyramidal. Single-crystal X-ray diffraction structures of some relevant bicyclic amides, including the prototype N-benzoyl-7-azabicyclo[2.2.1]heptane, exhibited nitrogen-pyramidalization in the solid state. We evaluated the rotational barriers about the amide bonds of various N-benzoyl-7-azabicyclo[2.2.1]heptanes in solution The observed reduction of the rotational barriers of the bicyclic amides, as compared with those of the monocyclic pyrrolidine amides, is consistent with a nitrogen-pyramidal structure of 7-azabicyclo[2.2.1]heptane amides in solution A good correlation was found between the magnitudes of the rotational barrier of N-benzoyl-7-azabicyclo[2.2.1]heptanes bearing para-substituents on the benzoyl group and the Hammett's σp+ consts., and this is consistent with the similarity of the solution structures. Calcns. with the d. functional theory reproduced the nitrogen-pyramidal structures of these bicyclic amides as energy min. The calculated magnitudes of electron delocalization from the nitrogen nonbonding nN orbital to the carbonyl π* orbital of the amide group evaluated by application of the bond model theory correlated well with the rotational barriers of a variety of amides, including amides of 7-azabicyclo[2.2.1]heptane. The nonplanarity of the amide nitrogen of 7-azabicyclo[2.2.1]heptanes would be derived from nitrogen-pyramidalization due to the CNC angle strain and twisting of the amide bond due to the allylic strain.
IT **643026-89-5P**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(evaluation of amide group planarity in azabicycloheptane amides)
RN 643026-89-5 HCAPLUS
CN Azetidine, 1-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:713343 HCAPLUS
DOCUMENT NUMBER: 135:272894
TITLE: Preparation of β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
INVENTOR(S): Duan, Jingwu; King, Bryan W.; Decicco, Carl; Maduskuie, Thomas P., Jr.; Voss, Matthew E.
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 483 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070734	A2	20010927	WO 2001-US8336	20010315
WO 2001070734	A3	20020314		
W: AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, HU, IL, IN, JP, KR, LT, LU, LV, NZ, PL, PT, RO, SE, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2400168	AA	20010927	CA 2001-2400168	20010315
AU 2001050850	A5	20011003	AU 2001-50850	20010315
EP 1263756	A2	20021211	EP 2001-924171	20010315
EP 1263756	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
BR 2001009469	A	20030429	BR 2001-9469	20010315
JP 2003528097	T2	20030924	JP 2001-568935	20010315
AT 260272	E	20040315	AT 2001-924171	20010315
NZ 521245	A	20040430	NZ 2001-521245	20010315
ES 2215893	T3	20041016	ES 2001-1924171	20010315
US 2002013341	A1	20020131	US 2001-811116	20010316
US 6495565	B2	20021217		
HK 1049334	A1	20040716	HK 2003-101437	20030226
PRIORITY APPLN. INFO.:			US 2000-190183P P	20000317
			US 2000-235467P P	20000926
			US 2000-252062P P	20001120
			WO 2001-US8336 W	20010315

OTHER SOURCE(S): MARPAT 135:272894
AB Novel β-amino acid derivs. A-CR3R4aCR2R4NR1CO-X-Z-Ua-Xa-Ya-Za [A = CO2H, SH, CH2SH, S(O)Ra:NH (Ra = H, alkyl), P(O)(OH)2, etc.; X, Xa is absent or alkylene, alkenylene or alkynylene; Z is absent or substituted C3-13 carbocycle or 5-14 membered heterocycle; Ua is absent or O, NRa1 [Ra1 = H, (un)substituted alkyl, alkenyl or alkynyl; Ra and Ra1 may form a ring], CO, CO2, O2C, CONRa1, S(O)p (p = 0-2), etc.; Ya is absent or O, NRa1, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered heterocycle; R1 is H, alkyl, Ph, benzyl; R2 is Q (Q is H, substituted

L4 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
carbocycle or heterocycle), alkylene-Q, (CRaRa1)r1O(CRaRa1)r-Q (r, r1 = 0-4), (CRaRa1)r1NRa(CRaRa1)r-Q, etc.; R3 = Q1 (Q1 is any group given for Q), alkylene-Q1, (CRaRa1)r1O(CRaRa1)r-Q1, (CRaRa1)r1NRa(CRaRa1)r-Q1, etc.;
R4, R4a = H, substituted alkyl, alkenyl or alkynyl; alternatively R1 and R2, R1 and R3, R3 and R4a may form rings (with provisos)] or a stereoisomer or pharmaceutically acceptable salt were prepd. as metalloprotease and TNF-α inhibitors. Thus, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-3-azetidinecarboxamide was prepd. by a multistep procedure involving reactions of Me 4-hydroxyphenylacetate, 2-methyl-4-quinolinylmethanol, and 3-azetidinecarboxylic acid Me ester.
IT **362697-32-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)
RN 362697-32-3 HCAPLUS
CN 3-Azetidinecarboxamide, N-hydroxy-1-[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]- (9CI) (CA INDEX NAME)



IT **362703-18-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)
RN 362703-18-2 HCAPLUS
CN 3-Azetidinecarboxylic acid, 1-[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:210150 HCAPLUS
DOCUMENT NUMBER: 132:251067
TITLE: Novel amidine derivatives, their preparation and application as inhibitors of NO synthase and lipid peroxidation, and pharmaceutical compositions containing them
INVENTOR(S): Auvin, Serge; Chabrier de Lassauniere, Pierre-Etienne; Harnett, Jeremiah; Pons, Dominique; Ulibarri, Gerard
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017190	A2	20000330	WO 1999-FR2250	19990922
WO 2000017190	A3	20001026		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2783519	A1	20000324	FR 1998-11868	19980923
FR 2783519	B1	20030124		
CA 2344224	AA	20000330	CA 1999-2344224	19990922
AU 9956314	A1	20000410	AU 1999-56314	19990922
AU 766373	B2	20031016		
BR 9913904	A	20010703	BR 1999-13904	19990922
EP 1115719	A2	20010718	EP 1999-943024	19990922
EP 1115719	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526493	T2	20020820	JP 2000-574099	19990922
AT 233750	E	20030315	AT 1999-943024	19990922
EP 1318149	A1	20030611	EP 2002-26170	19990922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1115719	T	20030731	PT 1999-943024	19990922
NZ 511189	A	20030926	NZ 1999-511189	19990922
ES 2194501	T3	20031116	ES 1999-943024	19990922
RU 2238939	C2	20041027	RU 2001-111022	19990922
IL 141998	A1	20050925	IL 1999-141998	19990922
US 6653312	B1	20031125	US 2001-787467	20010316
NO 2001001479	A	20010518	NO 2001-1479	20010322
ZA 2001003204	A	20020919	ZA 2001-3204	20010419
HK 1042486	A1	20050225	HK 2002-103892	20020524
US 2005261269	A1	20051124	US 2003-662183	20030912
PRIORITY APPLN. INFO.:			FR 1998-11868 A	19980923
			EP 1999-943024 A3	19990922

L4 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
WO 1999-FR2250 W 19990922
US 2001-787467 A3 20010316

OTHER SOURCE(S): MARPAT 132:251067
GI



I



II

AB The invention concerns novel amidine derivs., including compds. I [R = H, alkyl, alkoxy; A = certain substituted aryl or (un)substituted heteroaryl groups; B = alkyl, (un)substituted aryl or heteroaryl, (un)substituted or heterocyclic amino; X = bond, (CH2)m, O(CH2)m, (CH2)mO, S(CH2)m, O(CH2)mCO, CH:CH, etc.; Y = bond, (CH2)n, (CH2)rQ(CH2)s; Q = piperazine, homopiperazine, piperidine, pyrrolidine, azetidine, thiazolidine, saturated C3-7 carbocycles, etc; Z = bond, (CH2)pO(CH2)q, (CH2)pS(CH2)q, (CH2)pNH(CH2)q, etc; m, n, p, q, r, s = 0-6], as well as addnl. specific compds. In particular, 2-hydroxy-5-methoxy-N-[2-[4-[(2-thienyliminomethyl)amino]phenyl]ethyl]benzamide (II) and 2,5-dihydroxy-N-[2-[4-[(2-thienyliminomethyl)amino]phenyl]ethyl]benzamide are disclosed. Also disclosed are the use of I as medicines, and pharmaceutical compns. containing them. For instance, amidation of 5-methoxysalicylic acid with 4-nitrophenethylamine-HCl, followed by hydrogenation of the nitro group to amino, condensation of the amine with S-methyl-2-thiophenethiocarboximide-HI, and acidification in acetone, gave II.HCl. The IC50 of selected I, including II.HCl, against rat neuronal NO synthase in vitro, was < 3.5 μM.

IT **262614-42-6P 262614-43-7P**

L4 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of amidine derivs. as inhibitors of NO synthase and/or lipid peroxidn.)

RN 262614-42-6 HCAPLUS
CN Carbamic acid, [4-[1-(2-hydroxy-4,6-dimethoxybenzoyl)-3-azetidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 262614-43-7 HCAPLUS
CN Azetidine, 3-(4-aminophenyl)-1-(2-hydroxy-4,6-dimethoxybenzoyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:613831 HCAPLUS
DOCUMENT NUMBER: 127:278203
TITLE: Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
INVENTOR(S): Bock, Mark G.; Evans, Ben E.; Williams, Peter D.; Freidinger, Roger M.; Pettibone, Douglas J.; Hobbs, Doug W.; Anderson, Paul S.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 140 pp., Cont.-in-part of U.S. Ser. No. 92,840, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5665719	A	19970909	US 1995-470693	19950606
PRIORITY APPLN. INFO.:			US 1993-92840	B2 19930716

OTHER SOURCE(S): MARPAT 127:278203
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Compds. of formula I [X = O, NH, or NR8; Y = CH2, CHR8, or C(R8)2; R1 = camphor-10-yl, alkoxy, styryl, hydroxystyryl, furyl, (un)substituted thienyl, naphthyl, indolyl, tetrahydronaphthyl, (un)substituted pyridyl, pyrazinyl, (un)substituted cyclohexyl or Ph; R2 = H, alkoxy, alkyl, amino, alkylcarbonylamino, nitro, or halo; R3 = H, alkoxycarbonyl, cyano, or carbamoyl; and m = 0 or 1] and various analogs are disclosed. The compds. as useful as oxytocin (OT) and vasopressin receptor antagonists. Over 275 synthetic examples are given. For instance, Me 2,4-dihydroxybenzoate underwent Mitsunobu etherification with N-(tert-butoxycarbonyl)-4-piperidinol (51%), followed by O-methylation of the remaining hydroxyl (88%), saponification of the Me ester (95%), and coupling of the resultant acid with 1-(4-piperidinyl)-1,2-dihydro-4H-3,1-benzoxazin-2-one (HCl salt) using EDC and HOBt (88%), to give title compound II [R = CO2Bu-tert]. The latter was deprotected with HCl in dioxane (93%) and acetylated with Ac2O (89%) to give title compound II [R = Ac]. The latter inhibited binding of [3H]-OT to rat uterine OT receptors in vitro with an IC50 of 47 nM.

IT **162045-63-8P 162045-66-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzoxazinone and benzopyrimidinone derivs. as oxytocin and vasopressin receptor antagonists)

RN 162045-63-8 HCAPLUS
CN 3-Azetidinamine, 1-(2,4-dimethoxybenzoyl)-N-[2-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 162045-66-1 HCAPLUS
CN Benzenebutanoic acid, 2-[[1-(2,4-dimethoxybenzoyl)-3-azetidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT **162042-77-5P 162042-79-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoxazinone and benzopyrimidinone derivs. as oxytocin and vasopressin receptor antagonists)

RN 162042-77-5 HCAPLUS
CN Azetidine, 1-(2,4-dimethoxybenzoyl)-3-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl)- (9CI) (CA INDEX NAME)



RN 162042-79-7 HCAPLUS
CN Azetidine, 1-(2,4-dimethoxybenzoyl)-3-(2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:513507 HCAPLUS
DOCUMENT NUMBER: 125:131668
TITLE: 2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus
AUTHOR(S): Clader, John W.; Burnett, Duane A.; Caplen, Mary Ann; Domalski, Martin S.; Dugar, Sundeep; Vaccaro, Wayne; Sher, Rosy; Browne, Margaret E.; Zhao, Hongrong; et al.
CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ, 07033-0539, USA
SOURCE: Journal of Medicinal Chemistry (1996), 39(19), 3684-3693
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of azetidinone cholesterol absorption inhibitors related to SCH 48461 was prepared, and evaluated for their ability to inhibit hepatic cholesteryl ester formation in a cholesterol-fed hamster model. Although originally designed as acyl CoA:cholesterol acyltransferase (ACAT) inhibitors, comparison of in vivo potency with in vitro activity in a microsomal ACAT assay indicates no correlation between activity in these 2 models. The mol. mechanism by which these compds. inhibit cholesterol absorption is unknown. Despite this limitation, examination of the in vivo activity of a range of compds. has revealed clear structure-activity relationships consistent with a well-defined mol. target. The details of these structure-activity relationships and their implications on the nature of the putative pharmacophore are discussed.

IT **179763-35-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(structure-activity relations of azetidinone cholesterol absorption inhibitors)

RN 179763-35-0 HCAPLUS
CN 2-Azetidinone, 1-(4-methoxybenzoyl)-4-(4-methoxyphenyl)-3-(3-phenylpropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:954289 HCAPLUS
DOCUMENT NUMBER: 124:116909
TITLE: Simple and condensed β-lactams. Part 23. Synthesis of some compounds related to the monobactams, carrying non-acylamino substituents in position 3 and various heterocyclyl or heterocyclylmethyl substituents in position 4 of the β-lactam ring
AUTHOR(S): Fetter, Jozsef; Bertha, Ferenc; Czuppon, Tibor; Kajtar-Peredy, Maria; Lempert, Karoly
CORPORATE SOURCE: Dep. Org. Chem., Tech. Univ. Budapest, Budapest, H-1521, Hung.
SOURCE: Journal of Chemical Research, Synopses (1995), (11), 444-5
CODEN: JRPSDC; ISSN: 0308-2342
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:116909
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Thirteen new racemic monobactams, I (trans or cis, M = Na, H; R1 = alkyl, substituted alkyl; R2 = Me, NH2, NHCHO), II, III, IV (cis or trans, R3 = Et, CHMe2), V and VI, carrying non-acylamino substituents in position 3, and heterocyclyl or heterocyclylmethyl substituents in position 4 of the β-lactam ring, as well as 'reversed' monobactam analog, were synthesized. None of the prepared compds. exhibited any microbiol. activity.

IT **172698-00-9P**
RL: BYP (Byproduct); PREP (Preparation)
(synthesis of some compds. related to the monobactams and their antimicrobiol. activity)

RN 172698-00-9 HCAPLUS
CN 2-Azetidinone, 1-(2,4-dimethoxybenzoyl)-3-ethyl-4-[(4-methyl-2-thiazolyl)methyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:470323 HCAPLUS
DOCUMENT NUMBER: 123:276051
TITLE: Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
INVENTOR(S): Bock, Mark G.; Evans, Ben E.; Hobbs, Doug W.; Williams, Peter D.; Anderson, Paul S.; Freidinger, Roger M.; Pettibone, Douglas J.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 385 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9502405	A1	19950126	WO 1994-US7784	19940714
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2166975	AA	19950126	CA 1994-2166975	19940714
CA 2166975	C	20050405		
AU 9475132	A1	19950213	AU 1994-75132	19940714
AU 691829	B2	19980528		
EP 714299	A1	19960605	EP 1994-925092	19940714
EP 714299	B1	20020424		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09500134	T2	19970107	JP 1994-504656	19940714
AT 216580	E	20020515	AT 1994-925092	19940714
PRIORITY APPLN. INFO.:			US 1993-92840 A	19930716
			WO 1994-US7784 W	19940714

OTHER SOURCE(S): MARPAT 123:276051
GI



I

II

L4 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Fused N-containing heterocyclic ring system derivs. I [A completes a 5- or 6-membered carbocyclic or N- and/or S-containing heterocyclic ring; X = O, NH, (CH2)qO, CH2NH, OCH2, CH:CH, S, etc.; Y = CH2, C:O, C:S, C:NH, C:NMe; B = (substituted) N-containing heterocyclic or heterobicyclic ring; W = CH2, C:O, CO2, SO2, C(:NCH2Ph), etc.; R1 = (hetero)aryl, C1-5 alkoxy, camphor-10-yl] are useful as oxytocin and vasopressin receptor antagonists, e.g in treatment of preterm labor and dysmenorrhea and in stopping labor preparatory to cesarean delivery. Thus, in competitive radioligand binding assays on rat uterus membrane prepns., high-affinity binding of oxytocin-3H was inhibited by 1-[1-[4-[1-[(diethylaminoethyl)sulfonyl]-4-piperidinyloxy]-2-methoxybenzoyl]piperidin-4-yl]-1,2-dihydro-4H-3,1-benzoxazin-2-one (II) with an IC50 of 23 nM. II was prepared in 7 steps from Me 2,4-dihydroxybenzoate, N-tert-butyloxy-4-piperidinol, 1-(4-piperidinyl)-1,2-dihydro-4H-3,1-benzoxazin-2-one-HCl (preparation given), ClCH2CH2SO2Cl, and HNEt2. Preparation of 277 compds. of formula I is described.
IT **162042-77-5P 162042-79-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists)
RN 162042-77-5 HCAPLUS
CN Azetidine, 1-(2,4-dimethoxybenzoyl)-3-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl)- (9CI) (CA INDEX NAME)



RN 162042-79-7 HCAPLUS
CN Azetidine, 1-(2,4-dimethoxybenzoyl)-3-(2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **162045-63-8P 162045-66-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists)
RN 162045-63-8 HCAPLUS
CN 3-Azetidinamine, 1-(2,4-dimethoxybenzoyl)-N-[2-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 162045-66-1 HCAPLUS
CN Benzenebutanoic acid, 2-[[1-(2,4-dimethoxybenzoyl)-3-azetidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:44917 HCAPLUS
DOCUMENT NUMBER: 122:56244
TITLE: Topliss approach to the synthesis of biologically active substituted N-benzoyl taxol analogs
AUTHOR(S): Georg, Gunda I.; Boge, Thomas C.; Cheruvallath, Zacharia S.; Harriman, Geraldine C. B.; Hepperle, Michael; Park, Haeil; Himes, Richard H.
CORPORATE SOURCE: Dep. Med. Chem., Univ. Kansas, Lawrence, KS, 66045, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1994), 4(15), 1825-30
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of compds., e.g. I (R = Cl, MeO, 3,4-Cl2, Me2N, NO2, etc.), directed by the Topliss Operational Scheme, were synthesized and evaluated to investigate structure activity relationships of the N-benzoyl moiety of taxol. Evaluation of the newly prepared derivs. in the microtubule assembly assay and for cytotoxicity revealed that they possessed biol. properties similar to taxol.
IT **160058-87-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with triethylsilylbaccatin III in synthesis of taxol analogs)
RN 160058-87-7 HCAPLUS
CN 2-Azetidinone, 3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-(4-methoxybenzoyl)-4-phenyl-, (3R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:539574 HCAPLUS
DOCUMENT NUMBER: 119:139574
TITLE: Preparation of substituted isoserine esters using metal alkoxides and (beta)-lactams
INVENTOR(S): Holton, Robert A.
PATENT ASSIGNEE(S): Florida State University, USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 28
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9306079	A1	19930401	WO 1992-US7990	19920922
W: AU, CA, CS, FI, HU, JP, KP, KR, NO, PL, RU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
CA 2221190	C	20020212	CA 1992-2221190	19920902
ZA 9206827	A	19930315	ZA 1992-6827	19920908
ZA 9206828	A	19930315	ZA 1992-6828	19920908
ZA 9206829	A	19930315	ZA 1992-6829	19920908
ZA 9207038	A	19930514	ZA 1992-7038	19920915
ZA 9207039	A	19931220	ZA 1992-7039	19920915
CA 2098478	AA	19930324	CA 1992-2098478	19920922
CA 2098478	C	19990914		
AU 9226890	A1	19930427	AU 1992-26890	19920922
AU 647971	B2	19940331		
EP 605637	A1	19940713	EP 1992-921316	19920922
EP 605637	B1	19990324		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
JP 07502983	T2	19950330	JP 1993-506299	19920922
JP 3469237	B2	20031125		
HU 71795	A2	19960228	HU 1994-830	19920922
EP 884314	A2	19981216	EP 1998-114788	19920922
EP 884314	A3	20020502		
EP 884314	B1	20040121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
RU 2128654	C1	19990410	RU 1994-44324	19920922
AT 178060	E	19990415	AT 1992-921316	19920922
ES 2132129	T3	19990816	ES 1992-921316	19920922
CZ 287417	B6	20001115	CZ 1994-660	19920922
CZ 287609	B6	20010117	CZ 1994-661	19920922
EP 1193252	A2	20020403	EP 2002-688	19920922
EP 1193252	A3	20031105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
CA 2254273	C	20030325	CA 1992-2254273	19920922
AT 258171	E	20040215	AT 1998-114788	19920922
ES 2214665	T3	20040916	ES 1998-114788	19920922
AU 9339838	A1	19930819	AU 1993-39838	19930527
AU 642392	B3	19931014		
FI 9401325	A	19940504	FI 1994-1325	19940322
FI 113046	B1	20040227		
NO 9401022	A	19940520	NO 1994-1022	19940322
NO 306209	B1	19991004		

L4 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

TW 396159	B	20000701	TW 1994-83103422	19940418
US 5539103	A	19960723	US 1994-351532	19941207
US 5723634	A	19980303	US 1995-483309	19950607
US 6066747	A	20000523	US 1995-522307	19951030
US 6069260	A	20000530	US 1997-941640	19970930
US 6479678	B1	20021112	US 2000-517791	20000302
US 2001014746	A1	20010816	US 2001-804821	20010313
US 6562962	B2	20030513		
US 2003027855	A1	20030206	US 2002-208418	20020730
US 6710191	B2	20040323		
US 2003120096	A1	20030626	US 2002-289103	20021106
US 6683196	B2	20040127		
JP 2004043439	A2	20040212	JP 2003-128200	20030506
US 2004073048	A1	20040415	US 2003-673897	20030929
PRIORITY APPLN. INFO.:			US 1991-763805 A	19910923
			US 1992-862955 A	19920403
			US 1992-863840 A	19920406
			US 1992-863451 A	19920403
			US 1992-863849 A	19920406
			US 1992-900408 A	19920618
			CA 1992-2077394 A3	19920902
			CA 1992-2098478 A3	19920922
			CS 1994-660 A	19920922
			CS 1994-661 A	19920922
			EP 1992-921316 A3	19920922
			EP 1998-114788 A3	19920922
			JP 1993-506299 A3	19920922
			US 1992-949107 B3	19920922
			WO 1992-US7990 A	19920922
			US 1992-967998 B1	19921026
			WO 1994-US2382 W	19940304
			US 1994-263270 B1	19940621
			US 1994-314532 A1	19940928
			US 1994-351532 A3	19941207
			US 1995-483309 A3	19950607
			US 1996-607108 A1	19960226
			US 1997-941640 A1	19970930

L4 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

	US 2000-517791	A1 20000302
	US 2000-566970	A1 20000509
	US 2002-194343	A1 20020712
	US 2002-289103	A1 20021106

OTHER SOURCE(S): MARPAT 119:139574
GI



AB A metal alkoxide MOCE1E2E3 (M = alkali metal, E1, E2, E3 = H, aliphatic, aryl, alkanoyloxy) is reacted with a β-lactam I [R1 = (un)protected OH, SH, NH2, R2 = H, aliphatic, aryl, heteroaryl, R3, R4 = aliphatic, aryl, heteroaryl, acyl, R5 = acyl, carboxy, thiocarboxy, amido, sulfonyl, phosphoryl] to give isoserine esters R5NHCR3R4CR1R2CO2CE1E2E3 which are reacted with a metal derivative of a taxol derivative to give appropriately substituted isoserine esters, e.g. II.

IT **149197-26-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(sequential lithiation and esterification by azetidinone derivative of baccatin III derivative in preparation of taxol-related compound)

RN 149197-26-2 HCAPLUS
CN 2-Azetidinone, 4-(4-fluorophenyl)-1-(4-methoxybenzoyl)-3-[(triethylsilyl)oxy]-, (3R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:449694 HCAPLUS
DOCUMENT NUMBER: 119:49694
TITLE: Preparation of substituted taxanes as antitumor agents
INVENTOR(S): Holton, Robert A.; Nadizadeh, Hossain; Beidiger, Ronald J.; Kim, Seokchan
PATENT ASSIGNEE(S): Florida State University, USA
SOURCE: Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 28
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 534709	A1	19930331	EP 1992-308609	19920922
EP 534709	B1	20030115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5250683	A	19931005	US 1992-863451	19920403
CA 2077394	AA	19930324	CA 1992-2077394	19920902
CA 2077394	C	19990406		
CA 2221190	C	20020212	CA 1992-2221190	19920902
AU 9222124	A1	19930325	AU 1992-22124	19920904
AU 655493	B2	19941222		
ZA 9206827	A	19930315	ZA 1992-6827	19920908
ZA 9206828	A	19930315	ZA 1992-6828	19920908
ZA 9206829	A	19930315	ZA 1992-6829	19920908
ZA 9207038	A	19930514	ZA 1992-7038	19920915
ZA 9207039	A	19931220	ZA 1992-7039	19920915
FI 113173	B1	20040315	FI 1992-4228	19920921
NO 9203679	A	19930324	NO 1992-3679	19920922
NO 305205	B1	19990419		
HU 63155	A2	19930728	HU 1992-3024	19920922
HU 215110	B	19981228		
JP 06199824	A2	19940719	JP 1992-276765	19920922
JP 3182231	B2	20010703		
EP 884314	A2	19981216	EP 1998-114788	19920922
EP 884314	A3	20020502		
EP 884314	B1	20040121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
CZ 287417	B6	20001115	CZ 1994-660	19920922
CZ 287609	B6	20010117	CZ 1994-661	19920922
EP 1193252	A2	20020403	EP 2002-688	19920922
EP 1193252	A3	20031105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
AT 231139	E	20030215	AT 1992-308609	19920922
CA 2254273	C	20030325	CA 1992-2254273	19920922
ES 2191005	T3	20030901	ES 1992-308609	19920922
TW 396159	B	20000701	TW 1994-83103422	19940418
US 5539103	A	19960723	US 1994-351532	19941207
US 5723634	A	19980303	US 1995-483309	19950607
US 6066747	A	20000523	US 1995-522307	19951030
US 6069260	A	20000530	US 1997-941640	19970930

L4 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 6479678	B1	20021112	US 2000-517791	20000302
US 2001014746	A1	20010816	US 2001-804821	20010313
US 6562962	B2	20030513		
US 2003027855	A1	20030206	US 2002-208418	20020730
US 6710191	B2	20040323		
US 2003120096	A1	20030626	US 2002-289103	20021106
US 6683196	B2	20040127		
JP 2004043439	A2	20040212	JP 2003-128200	20030506
US 2004073048	A1	20040415	US 2003-673897	20030929

PRIORITY APPLN. INFO.:

US 1991-763805	A	19910923
US 1992-863451	A	19920403
US 1992-862955	A	19920403
US 1992-863840	A	19920406
US 1992-863849	A	19920406
US 1992-900408	A	19920618
CA 1992-2077394	A3	19920902
CA 1992-2098478	A3	19920922
CS 1994-660	A	19920922
CS 1994-661	A	19920922
EP 1992-921316	A3	19920922
EP 1998-114788	A3	19920922
JP 1993-506299	A3	19920922
US 1992-949107	B3	19920922
US 1992-967998	B1	19921026
WO 1994-US2382	W	19940304
US 1994-263270	B1	19940621
US 1994-314532	A1	19940928
US 1994-351532	A3	19941207
US 1995-483309	A3	19950607
US 1996-607108	A1	19960226
US 1997-941640	A1	19970930
US 2000-517791	A1	20000302

L4 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 2000-566970	A1	20000509
US 2002-194343	A1	20020712
US 2002-289103	A1	20021106

OTHER SOURCE(S): MARPAT 119:49694
GI



I

AB Taxane derivs. I [R1, R3 = Ph, naphthyl, PhCH2CH2, 4-QC6H4 (Q = Me, Me3C, MeO, Cl, Br, F, O2N), 1,3-benzodioxolan-5-yl, 3,4-(MeO)2C6H3; Z = OT1 (T1 = H, hydroxyl protecting group, COT2, where T2 = H, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl or monocyclic aryl); E1, E2 = H or certain functional groups which increase the water solubility of the taxane derivative], were prepared Thus, treatment of 7-triethylsilyl baccatin III in THF with BuLi at -45° followed by cis-1-benzoyl-1-triethylsilyloxy-4-(1-naphthyl)azetidin-2-one and subsequent desilylation (pyridine/aqueous HF in MeCN) gave 3'-desphenyl-3'-(1-naphthyl)taxol in 64% yield. Tubulin binding assays of the compds. were performed. The antitumor activity of compds. I were evaluated and claimed.

IT **148548-73-6 148549-01-3 148549-09-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with lithiated (triethylsilyl)baccatin III, in preparation of neoplasm inhibitor)

RN 148548-73-6 HCAPLUS
CN 2-Azetidinone, 1-(4-methoxybenzoyl)-4-phenyl-3-[(triethylsilyl)oxy]-, (3R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148549-01-3 HCAPLUS

L4 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Azetidinone, 4-(4-fluorophenyl)-1-(4-methoxybenzoyl)-3-[(triethylsilyl)oxy]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 148549-09-1 HCAPLUS
CN 2-Azetidinone, 1-(4-methoxybenzoyl)-4-(4-methoxyphenyl)-3-[(triethylsilyl)oxy]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:7966 HCAPLUS
DOCUMENT NUMBER: 110:7966
TITLE: Antiaromatic compounds. 23. Cycloadditions of N-acylimines to cyclobutadienes
AUTHOR(S): Michels, Gisbert; Regitz, Manfred; Hermesdorf, Michael; Schneider, Juergen
CORPORATE SOURCE: Fachber. Chem., Univ. Kaiserslautern, Kaiserslautern, D-6750, Fed. Rep. Ger.
SOURCE: Chemische Berichte (1988), 121(10), 1775-83
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 110:7966
GI



AB The cyclobutadienes I (R = Me3C, Me) add the benzaldehyde imines PhCH:NCOR1 (R1 = Me, Me3CCH2, Ph) to yield the oxaazabicyclo[4.2.0]octadienes II. Under thermal conditions (150-170 °C) III isomerize in each case to 2-azabicyclo[2.2.0]hexenes III and/or IV, which differ only in the configuration at C(3). Acid-catalyzed isomerization reactions of II (chloroform/trifluoroacetic acid) finally end up also in the formation of IV. The reaction of the N-acylimines of hexafluoroacetone with I (R = Me3C) leads also to the formation of oxaazabicyclo[4.2.0]octadienes. The reaction of I, (R = Me3C) with the N-alkoxycarbonyl-substituted imines produces an unusual result with the formation of the 3-azatricyclo[3.1.0.02,6]hexanes V (R1 = Me, R2 = Ph, R3 = H; R1 = Et, R2 = R3 = F3C) which can be transformed into bicyclic

L4 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
isomers.
IT **114692-73-8P 114692-75-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 114692-73-8 HCAPLUS
CN 2-Azabicyclo[2.2.0]hex-5-ene-4-carboxylic acid, 1,5,6-tris(1,1-dimethylethyl)-2-(4-methoxybenzoyl)-3,3-bis(trifluoromethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 114692-75-0 HCAPLUS
CN 2-Azabicyclo[2.2.0]hex-5-ene, 1,5,6-tris(1,1-dimethylethyl)-2-(4-methoxybenzoyl)-3,3-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1986:514779 HCAPLUS
DOCUMENT NUMBER: 105:114779
TITLE: Simple and condensed β-lactams. II. The synthesis of new diethyl 4-oxoazetidine-2,2-dicarboxylates and some manipulations of their functional groups and N-substituents
AUTHOR(S): Simig, Gyula; Fetter, Jozsef; Hornyak, Gyula; Zauer, Karoly; Doleschall, Gabor; Lempert, Karoly; Nyitrai, Jozsef; Gombos, Zsuzsa; Gizur, Tibor; et al.
CORPORATE SOURCE: Res. Group Alkaloid Chem., Hung. Acad. Sci., Budapest, H-1521, Hung.
SOURCE: Acta Chimica Hungarica (1985), 119(1), 17-32
CODEN: ACHUDC; ISSN: 0231-3146
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB A series of new N-aryl- and N-aralkyl-4-oxoazetidine-2,2-dicarboxylates I [R = Ph, substituted Ph, (un)substituted CH2Ph] has been obtained by the Bose-Sheehan synthesis. Partial deethoxycarbonylation of I by Krapcho's method furnished the monocarboxylic esters. Reduction of the ester group of the latter gave the hydroxymethyl derivs., whose hydroxyl groups were derivatized and replaced to give II (R1 = ONO2, OAc, O2CNHPh, O3SMe, halogen, cyano, N3, NH2, pyridinium). The N-substituent of II [R = CH2C6H4(OMe)2-2,4, R1 = O3SMe, cyano] was removed by the peroxydisulfate oxidation method.
IT **103864-98-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 103864-98-8 HCAPLUS
CN 2-Azetidineacetonitrile, 1-(2,4-dimethoxybenzoyl)-4-oxo- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1985:422390 HCAPLUS
DOCUMENT NUMBER: 103:22390
TITLE: Debenzylation of N-benzyl-β-lactams by use of anodic oxidation
AUTHOR(S): Mori, Miwako; Ban, Yoshio
CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, 060, Japan
SOURCE: Heterocycles (1985), 23(2), 317-23
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 103:22390
GI



AB Anodic oxidation of the methylene-β-lactam I (R = CH2Ph) in MeOH gave I (R = CHPhOMe) and II. Similar results were obtained with I (R = CH2C6H4CO2Me-4). Oxidation of I (R = CH2C6H4Me-4) gave I [R = CH(OMe)C6H4Me-4, CH2C6H4CH2OH-4, CH(OMe)C6H4CH2OH-4] and I (R = CH2C6H4OMe-4) gave I [R = CH(OMe)C6H4OMe-4, C(OMe)2C6H4OMe-4]. Acid hydrolysis of I [R = CH(OMe)C6H4R1; R1 = H, CO2Me, Me, OMe) gave I (R = H).
IT **96850-66-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 96850-66-7 HCAPLUS
CN 8-Azabicyclo[5.2.0]non-1-en-9-one, 8-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1984:610814 HCAPLUS
DOCUMENT NUMBER: 101:210814
TITLE: Chemical modification of sulfazecin. Synthesis of 4-methoxycarbonyl-2-azetidinone-1-sulfonic acid derivatives
AUTHOR(S): Kishimoto, Shoji; Sendai, Michiyuki; Tomimoto, Mitsumi; Hashiguchi, Shohei; Matsuo, Taisuke; Ochiai, Michihiko
CORPORATE SOURCE: Cent. Res. Div., Takeda Chem. Ind., Ltd., Osaka, 532, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1984), 32(7), 2646-59
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



II

AB In the course of the chemical modification of sulfazecin, 3-[2-(2-aminothiazol-4-yl)-(Zn)-2-(substituted oxyimino)acetamido]-4-methoxycarbonyl-2-azetidinone-1-sulfonic acids were synthesized from cis-1-(2,4-dimethoxybenzyl)-4-methoxycarbonyl-3-phthalimido-2-azetidinone (I). These new 4-substituted derivs. showed more potent antimicrobial activities against gram-neg. bacteria than did the corresponding 4-unsubstituted comounds, and the derivs. having 3,4-cis stereochem. were more active than the trans isomers, especially against P. aeruginosa and some β-lactamase-producing bacteria. The reported procedure for the cycloaddn. reaction used to prepare I was investigated in detail; by the use of 20% excess NEt3, I was easily obtained in 72% yield as colorless crystals. A possible intermediate in this cycloaddn. reaction, acyliminium salt (II), was isolated as crystals and converted into β-lactams by treatment with 1,8-diazabicyclo[5.4.0]-7-undecene.

IT **92973-54-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 92973-54-1 HCAPLUS

CN 2-Azetidinecarboxylic acid, 1-(2,4-dimethoxybenzoyl)-4-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1980:425983 HCAPLUS
DOCUMENT NUMBER: 93:25983
TITLE: Studies on the synthesis of chemotherapeutics. VIII. Stereoselective synthesis of 1,9b-dihydro-2H,4H-2-oxo-azeto[1,2-c][1,3]benzoxazine-4-carboxylic acid derivatives. (Studies on the syntheses of heterocyclic compounds. DCCCXIII)
AUTHOR(S): Kametani, Tetsuji; Kigasawa, Kazuo; Hiiragi, Mineharu; Wakisaka, Kikuo; Sugi, Hideo; Tanigawa, Keizo
CORPORATE SOURCE: Pharm. Inst., Tohoku Univ., Sendai, Japan
SOURCE: Yakugaku Zasshi (1979), 99(11), 1132-40
CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
OTHER SOURCE(S): CASREACT 93:25983
GI



I II III

AB Cyclization of the phthalimidoazetidinylacetates I (R = CH2CCl3, CH2C6H4NO2-p) gave stereoselectively the corresponding 1,2-benzo-3-oxacephams II together with a stereoisomer. The I were prepared via the cycloaddn. reaction of N-(2-benzyloxybenzylidene)-2,4-dimethoxybenzylamine with phthaloylglycyl chloride, followed by oxidative cleavage of 2,4-dimethoxybenzyl group of the adduct III. Deprotection of the N-phthaloyl and ester groups of II was also investigated.

IT **73902-73-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 73902-73-5 HCAPLUS

CN 2-Azetidinone, 3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-(2,4-dimethoxybenzoyl)-4-[2-(phenylmethoxy)phenyl]-, cis- (9CI) (CA INDEX NAME)

L4 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Relative stereochemistry.



```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     109.79     276.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -15.00     -15.00

FILE 'REGISTRY' ENTERED AT 14:21:05 ON 03 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 FEB 2006  HIGHEST RN 873294-13-4
DICTIONARY FILE UPDATES:   1 FEB 2006  HIGHEST RN 873294-13-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10804505\e2.str
```



Ak 1



15 1

chain nodes :
7 9 13 15 17 18 20
ring nodes :
1 2 3 4 5 6 8 10 11 12
chain bonds :
1-20 2-13 3-18 5-7 7-8 7-9 13-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-10 8-12 10-11 11-12
exact/norm bonds :
1-20 2-13 3-18 7-8 7-9 8-10 8-12 10-11 11-12 13-17
exact bonds :
5-7
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 8 :

G1:H,[*1]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:Atom
11:Atom 12:Atom 13:CLASS 15:CLASS 17:CLASS 18:CLASS 20:CLASS
Generic attributes :
15:
Number of Carbon Atoms : less than 7

L5 STRUCTURE UPLOADED

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	277.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-15.00

```
FILE 'REGISTRY' ENTERED AT 14:21:21 ON 03 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 FEB 2006  HIGHEST RN 873294-13-4
DICTIONARY FILE UPDATES:   1 FEB 2006  HIGHEST RN 873294-13-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s l5
SAMPLE SEARCH INITIATED 14:21:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    19769 TO ITERATE

 10.1% PROCESSED     2000 ITERATIONS                          0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       386964 TO   403796
PROJECTED ANSWERS:               0 TO        0

L6            0 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 14:21:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   393651 TO ITERATE
```

100.0% PROCESSED 393651 ITERATIONS 33 ANSWERS
SEARCH TIME: 00.00.08

L7 33 SEA SSS FUL L5

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	444.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-15.00

FILE 'HCAPLUS' ENTERED AT 14:21:57 ON 03 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 3 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 2 Feb 2006 (20060202/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l33
L33 NOT FOUND
The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l7
L8 17 L7

=> d ibib hitstr 1-17

L8 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1232819 HCAPLUS
DOCUMENT NUMBER: 144:102803
TITLE: Different Transition-State Structures for the Reactions of β-Lactams and Analogous β-Sultams with Serine β-Lactamases
AUTHOR(S): Tsang, Wing Y.; Ahmed, Naveed; Hinchliffe, Paul S.; Wood, J. Matthew; Harding, Lindsay P.; Laws, Andrew P.; Page, Michael I.
CORPORATE SOURCE: Department of Chemical and Biological Sciences, University of Huddersfield, Queensgate /Huddersfield, HD1 3DH, USA
SOURCE: Journal of the American Chemical Society (2005), 127(49), 17556-17564
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **873073-29-1P**
RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(different transition-state structures for reactions of β-lactams and analogous β-sultams with serine β-lactamases)
RN 873073-29-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:823313 HCAPLUS
DOCUMENT NUMBER: 143:229708
TITLE: A preparation of azetidine derivatives, useful as COX-1/COX-2 inhibitors
INVENTOR(S): Altisen, Rosa Cuberes; Constansa, Jordi Frigola; Alvarez, Mathieu Ines
PATENT ASSIGNEE(S): Spain
SOURCE: U.S. Pat. Appl. Publ., 21 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005182041	A1	20050818	US 2004-804505	20040319
ES 2244313	A1	20051201	ES 2004-363	20040216
WO 2005077896	A1	20050825	WO 2005-EP1657	20050216

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: ES 2004-363 A 20040216
US 2004-804505 A 20040319

OTHER SOURCE(S): MARPAT 143:229708
IT **862780-46-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of azetidine derivs. useful as COX-1/COX-2 inhibitors)
RN 862780-46-9 HCAPLUS
CN 3-Azetidinol, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT **862780-47-0P 862780-52-7P 862780-55-0P**
862780-56-1P 862780-57-2P 862780-58-3P
862780-60-7P 862780-61-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azetidine derivs. useful as COX-1/COX-2 inhibitors)
RN 862780-47-0 HCAPLUS
CN 3-Azetidinol, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 862780-52-7 HCAPLUS
CN Acetamide, N-[(2S,3R)-1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]-2-methyl-3-azetidinyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 862780-55-0 HCAPLUS
CN 3-Azetidinol, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 862780-56-1 HCAPLUS
CN Azetidine, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]-3-bromo- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 862780-57-2 HCAPLUS
CN 3-Azetidinol, 1-[3,5-bis(1,1-dimethylethyl)-4-methoxybenzoyl]- (9CI) (CA INDEX NAME)



RN 862780-58-3 HCAPLUS
CN 3-Azetidinol, 1-[4-hydroxy-3,5-bis(1-methylethyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 862780-60-7 HCAPLUS
CN 3-Azetidinol, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 862780-61-8 HCAPLUS
CN 3-Azetidinol, 1-[3,5-bis(1,1-dimethylethyl)-4-hydroxybenzoyl]-3-phenyl- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L8 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:310829 HCAPLUS
DOCUMENT NUMBER: 140:303552
TITLE: Preparation of β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
INVENTOR(S): Duan, Jingwu; King, Bryan W.; Decicco, Carl; Maduskuie, Thomas P.; Voss, Mathew E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 150 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004072802	A1	20040415	US 2002-267207	20021009
PRIORITY APPLN. INFO.:			US 2002-267207	20021009

OTHER SOURCE(S): MARPAT 140:303552
IT **362697-32-3P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)
RN 362697-32-3 HCAPLUS
CN 3-Azetidinecarboxamide, N-hydroxy-1-[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]- (9CI) (CA INDEX NAME)



IT **362703-18-2P**

L8 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)
RN 362703-18-2 HCAPLUS
CN 3-Azetidinecarboxylic acid, 1-[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:60463 HCAPLUS
DOCUMENT NUMBER: 140:111265
TITLE: Preparation of azetidinecarboxylic acid and pyrrolidinecarboxylic acid N-hydroxyamide derivatives as antibacterial agents
INVENTOR(S): Raju, Bore G.; Odowd, Hardwin; Gao, Hongwu; Patel, Dinesh V.; Trias, Joaquim
PATENT ASSIGNEE(S): Vicuron Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007444	A2	20040122	WO 2003-US21838	20030711
WO 2004007444	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492035	AA	20040115	CA 2003-2492035	20030711
EP 1539744	A2	20050615	EP 2003-748939	20030711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005536510	T2	20051202	JP 2004-521744	20030711
PRIORITY APPLN. INFO.:			US 2002-394862P P	20020711
			WO 2003-US21838 W	20030711

OTHER SOURCE(S): MARPAT 140:111265
IT **647856-14-2P**, (R)-1-(3,5-Diallyl-4-methoxybenzoyl)azetidine-2-carboxylic acid hydroxyamide **647856-15-3P**, (R)-1-(4-Methoxy-3,5-dipropylbenzoyl)azetidine-2-carboxylic acid hydroxyamide **647856-18-6P**, (R)-1-(4-Methoxy-3-propylbenzoyl)azetidine-2-carboxylic acid hydroxyamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antibacterial agent; preparation of azetidinecarboxylic acid and pyrrolidinecarboxylic acid N-hydroxyamide derivs. as antibacterial agents)
RN 647856-14-2 HCAPLUS
CN 2-Azetidinecarboxamide, N-hydroxy-1-(4-methoxy-3,5-di-2-propenylbenzoyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 647856-15-3 HCAPLUS
CN 2-Azetidinecarboxamide, N-hydroxy-1-(4-methoxy-3,5-dipropylbenzoyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 647856-18-6 HCAPLUS
CN 2-Azetidinecarboxamide, N-hydroxy-1-(4-methoxy-3-propylbenzoyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **647856-16-4**, (R)-1-(3,5-Diallyl-4-methoxybenzoyl)azetidine-2-carboxylic acid methyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of azetidinecarboxylic acid and pyrrolidinecarboxylic acid
N-hydroxyamide derivs. as antibacterial agents)
RN 647856-16-4 HCAPLUS
CN 2-Azetidinecarboxylic acid, 1-(4-methoxy-3,5-di-2-propenylbenzoyl)-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



L8 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:887103 HCAPLUS
DOCUMENT NUMBER: 140:93653
TITLE: An Evaluation of Amide Group Planarity in 7-Azabicyclo[2.2.1]heptane Amides. Low Amide Bond Rotation Barrier in Solution
AUTHOR(S): Otani, Yuko; Nagae, Osamu; Naruse, Yuji; Inagaki, Satoshi; Ohno, Masashi; Yamaguchi, Kentaro; Yamamoto, Gaku; Uchiyama, Masanobu; Ohwada, Tomohiko
CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo, Tokyo, 113-0033, Japan
SOURCE: Journal of the American Chemical Society (2003), 125(49), 15191-15199
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:93653
IT **643026-89-5P**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP
(Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(evaluation of amide group planarity in azabicycloheptane amides)
RN 643026-89-5 HCAPLUS
CN Azetidine, 1-(4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:713343 HCAPLUS
DOCUMENT NUMBER: 135:272894
TITLE: Preparation of β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
INVENTOR(S): Duan, Jingwu; King, Bryan W.; Decicco, Carl; Maduskuie, Thomas P., Jr.; Voss, Matthew E.
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 483 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070734	A2	20010927	WO 2001-US8336	20010315
WO 2001070734	A3	20020314		
W: AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, HU, IL, IN, JP, KR, LT, LU, LV, NZ, PL, PT, RO, SE, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2400168	AA	20010927	CA 2001-2400168	20010315
AU 2001050850	A5	20011003	AU 2001-50850	20010315
EP 1263756	A2	20021211	EP 2001-924171	20010315
EP 1263756	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
BR 2001009469	A	20030429	BR 2001-9469	20010315
JP 2003528097	T2	20030924	JP 2001-568935	20010315
AT 260272	E	20040315	AT 2001-924171	20010315
NZ 521245	A	20040430	NZ 2001-521245	20010315
ES 2215893	T3	20041016	ES 2001-924171	20010315
US 2002013341	A1	20020131	US 2001-811116	20010316
US 6495565	B2	20021217		
HK 1049334	A1	20040716	HK 2003-101437	20030226

PRIORITY APPLN. INFO.: US 2000-190183P P 20000317
US 2000-235467P P 20000926
US 2000-252062P P 20001120
WO 2001-US8336 W 20010315

OTHER SOURCE(S): MARPAT 135:272894
IT **362697-32-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)
RN 362697-32-3 HCAPLUS
CN 3-Azetidinecarboxamide, N-hydroxy-1-[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **362703-18-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of β-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-α)
RN 362703-18-2 HCAPLUS
CN 3-Azetidinecarboxylic acid, 1-[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L8 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:210150 HCAPLUS
DOCUMENT NUMBER: 132:251067
TITLE: Novel amidine derivatives, their preparation and application as inhibitors of NO synthase and lipid peroxidation, and pharmaceutical compositions containing them
INVENTOR(S): Auvin, Serge; Chabrier de Lassauniere, Pierre-Etienne; Harnett, Jeremiah; Pons, Dominique; Ulibarri, Gerard
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017190	A2	20000330	WO 1999-FR2250	19990922
WO 2000017190	A3	20001026		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2783519	A1	20000324	FR 1998-11868	19980923
FR 2783519	B1	20030124		
CA 2344224	AA	20000330	CA 1999-2344224	19990922
AU 9956314	A1	20000410	AU 1999-56314	19990922
AU 766373	B2	20031016		
BR 9913904	A	20010703	BR 1999-13904	19990922
EP 1115719	A2	20010718	EP 1999-943024	19990922
EP 1115719	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526493	T2	20020820	JP 2000-574099	19990922
AT 233750	E	20030315	AT 1999-943024	19990922
EP 1318149	A1	20030611	EP 2002-26170	19990922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PT 1115719	T	20030731	PT 1999-943024	19990922
NZ 511189	A	20030926	NZ 1999-511189	19990922
ES 2194501	T3	20031116	ES 1999-943024	19990922
RU 2238939	C2	20041027	RU 2001-111022	19990922
IL 141998	A1	20050925	IL 1999-141998	19990922
US 6653312	B1	20031125	US 2001-787467	20010316
NO 2001001479	A	20010518	NO 2001-1479	20010322
ZA 2001003204	A	20020919	ZA 2001-3204	20010419
HK 1042486	A1	20050225	HK 2002-103892	20020524
US 2005261269	A1	20051124	US 2003-662183	20030912

PRIORITY APPLN. INFO.:
FR 1998-11868 A 19980923
EP 1999-943024 A3 19990922

L8 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
WO 1999-FR2250 W 19990922
US 2001-787467 A3 20010316

OTHER SOURCE(S): MARPAT 132:251067
IT **262614-42-6P 262614-43-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of amidine derivs. as inhibitors of NO synthase and/or lipid peroxidn.)
RN 262614-42-6 HCAPLUS
CN Carbamic acid, [4-[1-(2-hydroxy-4,6-dimethoxybenzoyl)-3-azetidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 262614-43-7 HCAPLUS
CN Azetidine, 3-(4-aminophenyl)-1-(2-hydroxy-4,6-dimethoxybenzoyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:613831 HCAPLUS
DOCUMENT NUMBER: 127:278203
TITLE: Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
INVENTOR(S): Bock, Mark G.; Evans, Ben E.; Williams, Peter D.; Freidinger, Roger M.; Pettibone, Douglas J.; Hobbs, Doug W.; Anderson, Paul S.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 140 pp., Cont.-in-part of U.S. Ser. No. 92,840, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5665719	A	19970909	US 1995-470693	19950606
PRIORITY APPLN. INFO.:			US 1993-92840	B2 19930716

OTHER SOURCE(S): MARPAT 127:278203
IT **162045-63-8P 162045-66-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzoxazinone and benzopyrimidinone derivs. as
oxytocin and vasopressin receptor antagonists)
RN 162045-63-8 HCAPLUS
CN 3-Azetidinamine, 1-(2,4-dimethoxybenzoyl)-N-[2-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 162045-66-1 HCAPLUS
CN Benzenebutanoic acid, 2-[[1-(2,4-dimethoxybenzoyl)-3-azetidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **162042-77-5P 162042-79-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoxazinone and benzopyrimidinone derivs. as oxytocin and
vasopressin receptor antagonists)
RN 162042-77-5 HCAPLUS
CN Azetidine, 1-(2,4-dimethoxybenzoyl)-3-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl)- (9CI) (CA INDEX NAME)



RN 162042-79-7 HCAPLUS
CN Azetidine, 1-(2,4-dimethoxybenzoyl)-3-(2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl)- (9CI) (CA INDEX NAME)



L8 ANSWER 8 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L8 ANSWER 9 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:513507 HCAPLUS
DOCUMENT NUMBER: 125:131668
TITLE: 2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus
AUTHOR(S): Clader, John W.; Burnett, Duane A.; Caplen, Mary Ann; Domalski, Martin S.; Dugar, Sundeep; Vaccaro, Wayne; Sher, Rosy; Browne, Margaret E.; Zhao, Hongrong; et al.
CORPORATE SOURCE: Schering-Plough Research Institute, Kenilworth, NJ, 07033-0539, USA
SOURCE: Journal of Medicinal Chemistry (1996), 39(19), 3684-3693
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **179763-35-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(structure-activity relations of azetidinone cholesterol absorption inhibitors)
RN 179763-35-0 HCAPLUS
CN 2-Azetidinone,
1-(4-methoxybenzoyl)-4-(4-methoxyphenyl)-3-(3-phenylpropyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:954289 HCAPLUS
DOCUMENT NUMBER: 124:116909
TITLE: Simple and condensed β-lactams. Part 23. Synthesis of some compounds related to the monobactams, carrying non-acylamino substituents in position 3 and various heterocyclyl or heterocyclylmethyl substituents in position 4 of the β-lactam ring
AUTHOR(S): Fetter, Jozsef; Bertha, Ferenc; Czuppon, Tibor; Kajtar-Peredy, Maria; Lempert, Karoly
CORPORATE SOURCE: Dep. Org. Chem., Tech. Univ. Budapest, Budapest, H-1521, Hung.
SOURCE: Journal of Chemical Research, Synopses (1995), (11), 444-5
CODEN: JRPSDC; ISSN: 0308-2342
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:116909
IT **172698-00-9P**
RL: BYP (Byproduct); PREP (Preparation)
(synthesis of some compds. related to the monobactams and their antimicrobiol. activity)
RN 172698-00-9 HCAPLUS
CN 2-Azetidinone, 1-(2,4-dimethoxybenzoyl)-3-ethyl-4-[(4-methyl-2-thiazolyl)methyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:470323 HCAPLUS
DOCUMENT NUMBER: 123:276051
TITLE: Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
INVENTOR(S): Bock, Mark G.; Evans, Ben E.; Hobbs, Doug W.; Williams, Peter D.; Anderson, Paul S.; Freidinger, Roger M.; Pettibone, Douglas J.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 385 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9502405	A1	19950126	WO 1994-US7784	19940714
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2166975	AA	19950126	CA 1994-2166975	19940714
CA 2166975	C	20050405		
AU 9475132	A1	19950213	AU 1994-75132	19940714
AU 691829	B2	19980528		
EP 714299	A1	19960605	EP 1994-925092	19940714
EP 714299	B1	20020424		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09500134	T2	19970107	JP 1994-504656	19940714
AT 216580	E	20020515	AT 1994-925092	19940714
PRIORITY APPLN. INFO.:			US 1993-92840	A 19930716
			WO 1994-US7784	W 19940714

OTHER SOURCE(S): MARPAT 123:276051
IT **162042-77-5P 162042-79-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists)
RN 162042-77-5 HCAPLUS
CN Azetidine, 1-(2,4-dimethoxybenzoyl)-3-(2-oxo-2H-3,1-benzoxazin-1(4H)-yl)- (9CI) (CA INDEX NAME)



RN 162042-79-7 HCAPLUS
CN Azetidine, 1-(2,4-dimethoxybenzoyl)-3-(2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-yl)- (9CI) (CA INDEX NAME)



IT **162045-63-8P 162045-66-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists)
RN 162045-63-8 HCAPLUS
CN 3-Azetidinamine, 1-(2,4-dimethoxybenzoyl)-N-[2-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 162045-66-1 HCAPLUS
CN Benzenebutanoic acid, 2-[[1-(2,4-dimethoxybenzoyl)-3-azetidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:44917 HCAPLUS
DOCUMENT NUMBER: 122:56244
TITLE: Topliss approach to the synthesis of biologically active substituted N-benzoyl taxol analogs
AUTHOR(S): Georg, Gunda I.; Boge, Thomas C.; Cheruvallath, Zacharia S.; Harriman, Geraldine C. B.; Hepperle, Michael; Park, Haeil; Himes, Richard H.
CORPORATE SOURCE: Dep. Med. Chem., Univ. Kansas, Lawrence, KS, 66045, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1994), 4(15), 1825-30
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **160058-87-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with triethylsilylbaccatin III in synthesis of
taxol analogs)
RN 160058-87-7 HCAPLUS
CN 2-Azetidinone, 3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-(4-methoxybenzoyl)-4-phenyl-, (3R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:539574 HCAPLUS
DOCUMENT NUMBER: 119:139574
TITLE: Preparation of substituted isoserine esters using metal alkoxides and (beta)-lactams
INVENTOR(S): Holton, Robert A.
PATENT ASSIGNEE(S): Florida State University, USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 28
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9306079	A1	19930401	WO 1992-US7990	19920922
W: AU, CA, CS, FI, HU, JP, KP, KR, NO, PL, RU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
CA 2221190	C	20020212	CA 1992-2221190	19920902
ZA 9206827	A	19930315	ZA 1992-6827	19920908
ZA 9206828	A	19930315	ZA 1992-6828	19920908
ZA 9206829	A	19930315	ZA 1992-6829	19920908
ZA 9207038	A	19930514	ZA 1992-7038	19920915
ZA 9207039	A	19931220	ZA 1992-7039	19920915
CA 2098478	AA	19930324	CA 1992-2098478	19920922
CA 2098478	C	19990914		
AU 9226890	A1	19930427	AU 1992-26890	19920922
AU 647971	B2	19940331		
EP 605637	A1	19940713	EP 1992-921316	19920922
EP 605637	B1	19990324		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
JP 07502983	T2	19950330	JP 1993-506299	19920922
JP 3469237	B2	20031125		
HU 71795	A2	19960228	HU 1994-830	19920922
EP 884314	A2	19981216	EP 1998-114788	19920922
EP 884314	A3	20020502		
EP 884314	B1	20040121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
RU 2128654	C1	19990410	RU 1994-44324	19920922
AT 178060	E	19990415	AT 1992-921316	19920922
ES 2132129	T3	19990816	ES 1992-921316	19920922
CZ 287417	B6	20001115	CZ 1994-660	19920922
CZ 287609	B6	20010117	CZ 1994-661	19920922
EP 1193252	A2	20020403	EP 2002-688	19920922
EP 1193252	A3	20031105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
CA 2254273	C	20030325	CA 1992-2254273	19920922
AT 258171	E	20040215	AT 1998-114788	19920922
ES 2214665	T3	20040916	ES 1998-114788	19920922
AU 9339838	A1	19930819	AU 1993-39838	19930527
AU 642392	B3	19931014		
FI 9401325	A	19940504	FI 1994-1325	19940322
FI 113046	B1	20040227		
NO 9401022	A	19940520	NO 1994-1022	19940322
NO 306209	B1	19991004		

L8 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

TW 396159	B	20000701	TW 1994-83103422	19940418
US 5539103	A	19960723	US 1994-351532	19941207
US 5723634	A	19980303	US 1995-483309	19950607
US 6066747	A	20000523	US 1995-522307	19951030
US 6069260	A	20000530	US 1997-941640	19970930
US 6479678	B1	20021112	US 2000-517791	20000302
US 2001014746	A1	20010816	US 2001-804821	20010313
US 6562962	B2	20030513		
US 2003027855	A1	20030206	US 2002-208418	20020730
US 6710191	B2	20040323		
US 2003120096	A1	20030626	US 2002-289103	20021106
US 6683196	B2	20040127		
JP 2004043439	A2	20040212	JP 2003-128200	20030506
US 2004073048	A1	20040415	US 2003-673897	20030929
PRIORITY APPLN. INFO.:			US 1991-763805	A 19910923
			US 1992-862955	A 19920403
			US 1992-863840	A 19920406
			US 1992-863451	A 19920403
			US 1992-863849	A 19920406
			US 1992-900408	A 19920618
			CA 1992-2077394	A3 19920902
			CA 1992-2098478	A3 19920922
			CS 1994-660	A 19920922
			CS 1994-661	A 19920922
			EP 1992-921316	A3 19920922
			EP 1998-114788	A3 19920922
			JP 1993-506299	A3 19920922
			US 1992-949107	B3 19920922
			WO 1992-US7990	A 19920922
			US 1992-967998	B1 19921026
			WO 1994-US2382	W 19940304
			US 1994-263270	B1 19940621
			US 1994-314532	A1 19940928
			US 1994-351532	A3 19941207
			US 1995-483309	A3 19950607
			US 1996-607108	A1 19960226
			US 1997-941640	A1 19970930

L8 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

			US 2000-517791	A1 20000302
			US 2000-566970	A1 20000509
			US 2002-194343	A1 20020712
			US 2002-289103	A1 20021106

OTHER SOURCE(S): MARPAT 119:139574
IT **149197-26-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(sequential lithiation and esterification by azetidinone derivative of baccatin III derivative in preparation of taxol-related compound)
RN 149197-26-2 HCAPLUS
CN 2-Azetidinone, 4-(4-fluorophenyl)-1-(4-methoxybenzoyl)-3-[(triethylsilyl)oxy]-, (3R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:449694 HCAPLUS
DOCUMENT NUMBER: 119:49694
TITLE: Preparation of substituted taxanes as antitumor agents
INVENTOR(S): Holton, Robert A.; Nadizadeh, Hossain; Beidiger, Ronald J.; Kim, Seokchan
PATENT ASSIGNEE(S): Florida State University, USA
SOURCE: Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 28
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 534709	A1	19930331	EP 1992-308609	19920922
EP 534709	B1	20030115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5250683	A	19931005	US 1992-863451	19920403
CA 2077394	AA	19930324	CA 1992-2077394	19920902
CA 2077394	C	19990406		
CA 2221190	C	20020212	CA 1992-2221190	19920902
AU 9222124	A1	19930325	AU 1992-22124	19920904
AU 655493	B2	19941222		
ZA 9206827	A	19930315	ZA 1992-6827	19920908
ZA 9206828	A	19930315	ZA 1992-6828	19920908
ZA 9206829	A	19930315	ZA 1992-6829	19920908
ZA 9207038	A	19930514	ZA 1992-7038	19920915
ZA 9207039	A	19931220	ZA 1992-7039	19920915
FI 113173	B1	20040315	FI 1992-4228	19920921
NO 9203679	A	19930324	NO 1992-3679	19920922
NO 305205	B1	19990419		
HU 63155	A2	19930728	HU 1992-3024	19920922
HU 215110	B	19981228		
JP 06199824	A2	19940719	JP 1992-276765	19920922
JP 3182231	B2	20010703		
EP 884314	A2	19981216	EP 1998-114788	19920922
EP 884314	A3	20020502		
EP 884314	B1	20040121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
CZ 287417	B6	20001115	CZ 1994-660	19920922
CZ 287609	B6	20010117	CZ 1994-661	19920922
EP 1193252	A2	20020403	EP 2002-688	19920922
EP 1193252	A3	20031105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, IE				
AT 231139	E	20030215	AT 1992-308609	19920922
CA 2254273	C	20030325	CA 1992-2254273	19920922
ES 2191005	T3	20030901	ES 1992-308609	19920922
TW 396159	B	20000701	TW 1994-83103422	19940418
US 5539103	A	19960723	US 1994-351532	19941207
US 5723634	A	19980303	US 1995-483309	19950607
US 6066747	A	20000523	US 1995-522307	19951030
US 6069260	A	20000530	US 1997-941640	19970930

L8 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 6479678	B1	20021112	US 2000-517791	20000302
US 2001014746	A1	20010816	US 2001-804821	20010313
US 6562962	B2	20030513		
US 2003027855	A1	20030206	US 2002-208418	20020730
US 6710191	B2	20040323		
US 2003120096	A1	20030626	US 2002-289103	20021106
US 6683196	B2	20040127		
JP 2004043439	A2	20040212	JP 2003-128200	20030506
US 2004073048	A1	20040415	US 2003-673897	20030929
PRIORITY APPLN. INFO.:			US 1991-763805	A 19910923
			US 1992-863451	A 19920403
			US 1992-862955	A 19920403
			US 1992-863840	A 19920406
			US 1992-863849	A 19920406
			US 1992-900408	A 19920618
			CA 1992-2077394	A3 19920902
			CA 1992-2098478	A3 19920922
			CS 1994-660	A 19920922
			CS 1994-661	A 19920922
			EP 1992-921316	A3 19920922
			EP 1998-114788	A3 19920922
			JP 1993-506299	A3 19920922
			US 1992-949107	B3 19920922
			US 1992-967998	B1 19921026
			WO 1994-US2382	W 19940304
			US 1994-263270	B1 19940621
			US 1994-314532	A1 19940928
			US 1994-351532	A3 19941207
			US 1995-483309	A3 19950607
			US 1996-607108	A1 19960226
			US 1997-941640	A1 19970930
			US 2000-517791	A1 20000302

L8 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

			US 2000-566970	A1 20000509
			US 2002-194343	A1 20020712
			US 2002-289103	A1 20021106

OTHER SOURCE(S): MARPAT 119:49694
IT **148548-73-6 148549-01-3 148549-09-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with lithiated (triethylsilyl)baccatin III, in preparation of
neoplasm inhibitor)
RN 148548-73-6 HCAPLUS
CN 2-Azetidinone, 1-(4-methoxybenzoyl)-4-phenyl-3-[(triethylsilyl)oxy]-, (3R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148549-01-3 HCAPLUS
CN 2-Azetidinone, 4-(4-fluorophenyl)-1-(4-methoxybenzoyl)-3-[(triethylsilyl)oxy]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 148549-09-1 HCAPLUS
CN 2-Azetidinone, 1-(4-methoxybenzoyl)-4-(4-methoxyphenyl)-3-[(triethylsilyl)oxy]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1986:514779 HCAPLUS
DOCUMENT NUMBER: 105:114779
TITLE: Simple and condensed β-lactams. II. The synthesis of new diethyl 4-oxoazetidine-2,2-dicarboxylates and some manipulations of their functional groups and N-substituents
AUTHOR(S): Simig, Gyula; Fetter, Jozsef; Hornyak, Gyula; Zauer, Karoly; Doleschall, Gabor; Lempert, Karoly; Nyitrai, Jozsef; Gombos, Zsuzsa; Gizur, Tibor; et al.
CORPORATE SOURCE: Res. Group Alkaloid Chem., Hung. Acad. Sci., Budapest, H-1521, Hung.
SOURCE: Acta Chimica Hungarica (1985), 119(1), 17-32
CODEN: ACHUDC; ISSN: 0231-3146
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **103864-98-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 103864-98-8 HCAPLUS
CN 2-Azetidineacetonitrile, 1-(2,4-dimethoxybenzoyl)-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:610814 HCAPLUS
DOCUMENT NUMBER: 101:210814
TITLE: Chemical modification of sulfazecin. Synthesis of 4-methoxycarbonyl-2-azetidinone-1-sulfonic acid derivatives
AUTHOR(S): Kishimoto, Shoji; Sendai, Michiyuki; Tomimoto, Mitsumi; Hashiguchi, Shohei; Matsuo, Taisuke; Ochiai, Michihiko
CORPORATE SOURCE: Cent. Res. Div., Takeda Chem. Ind., Ltd., Osaka, 532, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1984), 32(7), 2646-59
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **92973-54-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 92973-54-1 HCAPLUS
CN 2-Azetidinecarboxylic acid, 1-(2,4-dimethoxybenzoyl)-4-oxo-3-[[(phenylmethoxy)carbonyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1980:425983 HCAPLUS
DOCUMENT NUMBER: 93:25983
TITLE: Studies on the synthesis of chemotherapeutics. VIII. Stereoselective synthesis of 1,9b-dihydro-2H,4H-2-oxo-azeto[1,2-c][1,3]benzoxazine-4-carboxylic acid derivatives. (Studies on the syntheses of heterocyclic compounds. DCCCXIII)
AUTHOR(S): Kametani, Tetsuji; Kigasawa, Kazuo; Hiiragi, Minehara; Wakisaka, Kikuo; Sugi, Hideo; Tanigawa, Keizo
CORPORATE SOURCE: Pharm. Inst., Tohoku Univ., Sendai, Japan
SOURCE: Yakugaku Zasshi (1979), 99(11), 1132-40
CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
OTHER SOURCE(S): CASREACT 93:25983
IT **73902-73-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 73902-73-5 HCAPLUS
CN 2-Azetidinone, 3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-(2,4-dimethoxybenzoyl)-4-[2-(phenylmethoxy)phenyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



Andrew Freistein 10/804,505

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	67.26	511.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-15.00

STN INTERNATIONAL LOGOFF AT 14:23:54 ON 03 FEB 2006